1,721,096 research outputs found
Chronic myeloid leukemia. Drug selection in first-line therapy and beyond
No full textThe current guidelines for chronic myeloid leukemia (CML) endorse the tyrosine kinase inhibitors (TKIs) imatinib, nilotinib and dasatinib for front-line therapy of CML in chronic phase (CP) and, consequently, physicians and patients face a difficult choice. There is no difference in overall survival between these TKIs. Choice of front-line treatment should be based on additional considerations: age, prognostic category, safety of the drug, the possibility of a deep and sustained response (treatment free remission, TFR). Whatever TKI is used first, current guidelines include milestones of optimal response (and failure) earlier than before, and a timely monitoring and treatment optimization, as early as after three months from starting front-line treatment, drives the treatment strategy. If the most important end point of treatment is overall survival, and the definitive cure of CML remains elusive for most patients, a survival free of treatment, a “treatment free remission”, may be achievable and may be particularly attractive for younger patients
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
No full textResults from several trials in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) of dasatinib and nilotinib, two BCR-ABL inhibitors with higher in vitro potency compared with imatinib, have recently been reported. In this review, the rationale for assessing dasatinib and nilotinib in the frontline setting is discussed and data from clinical trials performed to date are summarized, including single-arm studies and randomized trials compared with imatinib. Overall, both dasatinib and nilotinib have shown superior efficacy compared with imatinib during the first year of treatment and longer-term follow-up is needed to confirm that this superiority is maintained over time. Both agents have also shown favorable tolerability profiles, although distinct patterns of adverse events are seen with each agent. Clinicians now have several effective options to treat patients newly diagnosed with CML-CP and available data suggest that dasatinib and nilotinib represent improved therapeutic options compared with imatinib
Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
No full textNilotinib is a rationally designed tyrosine kinase inhibitor with improved specificity and binding affinity for BCR-ABL compared with imatinib. Nilotinib is approved in patients with imatinib-resistant and -intolerant Philadelphia chromosome-positive chronic myeloid leukemia (CML), as well as in patients with newly diagnosed CML. Nilotinib is generally well tolerated, with mild and manageable side effects, and is associated with some adverse events that require management to insure patient adherence to therapy and optimal treatment outcomes. The objectives of this article are to review the clinical management of the most frequent of these adverse events and to guide physicians in helping their patients maintain adherence and achieve optimal outcomes with nilotinib therapy
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib
No full textThe disease burden in chronic myeloid leukemia (CML) is linked to the activity of its chimeric oncoprotein, the BCR-ABL1 tyrosine kinase. A recent analysis of the IRIS study showed that imatinib, the first tyrosine kinase inhibitors (TKI), resulted in impressive survival and freedom from disease progression in chronic phase patients. However, 20–30% of these patients eventually develop resistance; due largely to mutations at the ABL1 kinase domain
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.
No full textDispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
- …
